Alternative applications for drug delivery: Nasal and pulmonary routes

Nanomaterials and Nanosystems for Biomedical Applications

Volumn , Issue , 2007, Pages 99-112

  Ozer, A Yekta ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

drug delivery systems; liposomes; microspheres; nasal drug delivery; peptide delivery; protein delivery; pulmonary drug delivery

Indexed keywords

EID: 80054808317     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-6289-6_6     Document Type: Chapter

References (70)

1. Wermeling DP, Miller JL. Intranasal Drug Delivery. In: Modified Release Drug Delivery Technology. J Swarbrick (Ex. Ed.), MJ Rathbone, I Hadgraft, MS Roberts (Eds), Marcell Dekker Inc, NewYork-Basel, pp: 727-748 (2003).
2. Ozer AY. Importance of Intranasal Route for Application of Drugs and Nasal Drug Delivery Systems. Pharmacia-JTPA, 30 136-147 (1990).
3. Turker S, Onur E, Ozer AY. Nasal Route and Drug Delivery Systems. Pharm World Sci, 26 137-142 (2004).
4. Chien YW, Su K S E, Chang SF. Anatomy and Physiology of Nose. In: Nasal Systemic Drug Delivery. YW Chien, KSE Su, SF Chang (Eds), Marcel Dekker Inc., New York, 1-26 (1989).
5. Celebi N. Nasal and Pulmonary Systems. In: Controlled Drug Delivery Systems. AZ Gursoy (Ed), Elma Bilgisayar Basim, Istanbul, pp: 217-237 (2002).
6. Sarkar MA. Drug Metabolism in the Nasal Mucosa. Pharm. Res. 9 1-9 (1992).
7. Brime B, Ballesteros MP, Frutos P. Preparation and In Vitro Characterization of Gelatin Microspheres Containing Levodopa for Nasal Administration. J. Microencap, 6 777-784 (2000).
8. Mygind N, Dahl R. Anatomy, Physiology and Function of the Nasal Cavities in Health and Disease. Adv. Drug Del. Rev. 29 3-12 (1998).
9. Marttin E, Verhoef JC, Cullander C, Romeijn SG, Nagelkerke JF, Merkus F H M. Confocal Laser Scanning Microscopic Visualization of the Transport of Dextran after Nasal Administration to Rats: Effects of Absorption Enhancers. Pharm. Res. 14 631-637 (1997).
10. Chien YW, Chang S. Intranasal Drug Delivery for Systemic Medication. Crit. Rev. Ther. Drug Carr. Syst. 4 67-194 (1987).
11. Hehar SS, Mason J D T, Stephen AB, Washington N, Jones NS, Jackson SJ, Bush D. Twenty Four Hour Ambulatory Nasal pH Monitoring. Clin. Otorynolaryngol, 24 24-25 (1999).
12. Schipper N G M, Verhoef JC, Merkus F W HM. The Nasal Mucociliary Clearance of Relevance to Nasal Drug Delivery. Pharm. Res. 8 807-814 (1991).
13. Duchateau G S MJE, Graamans K, Zuidema J, Merkus F W HM. Correlation Between Nasal Ciliary Heat Frequency and Mucus Transport Rate in Volunteers. Laryngoscope, 95 854-859 (1985).
14. Ugwoke, MI, Verbeke N, Kinget R. The Biopharmaceutical Aspects of Nasal Mucoadhesive Delivery. J. Pharm. Pharmacol. 57 3-21 (2001).
15. Chien YW. Nasal Drug Delivery Systems. In: J Swarbrick (Ed), Novel Drug Delivery Systems. New York, Marcel Dekker, pp: 139-196 (1992).
16. Hussain A. Intranasal Drug Delivery. Adv. Drug Del. Rev. 29 39-49 (1998).
17. Fisher AN, Brown K, Davis SS, Parr GD, Smith DA. The Effect of Molecular Size on the Nasal Absorption of Water-Soluble Compounds in the Albino Rat. J. Pharm. Pharmacol. 39 357-362 (1987).
18. Marttin E, Schipper N G M, Verhoef JC, Mercus W H M. Nasal Mucociliary Clearance as a Factor in Nasal Drug Delivery. Adv. Drug. Del. Rev. 29 13-38 (1998).
19. Hasani A, Agnew JE, Pavia D, Vora H, Clarke SW. Effect of Oral Bronchodilators on Lung Mucociliary Clearance During Sleep in Patients with Asthma. Thorax, 48 287-289 (1993).
20. Wolff RK, Dolovich MB, Obminski G, Newhouse MT. Effects of Exercise and Eucapric Hyperventilation on Bronchial Clearance in Man. J. Appl. Physiol. 43 46-50 (1977).
21. Verra F, Escuider E, Lebargy F, Bernaudin JF, Cremoux HD, Bignon J. Ciliary Abnormalities in Bronchial Ephitelium of Smokers, Ex-Smokers and non-smokers. Am. J. Respir. Crit. Care Med, 151 630-634 (1995).
22. Haxel BR, Schafer D, Klimek L. Prostaglandin E2 Activates the Ciliary Beat Frequency of Cultured Human Nasal Mucosa via the Second Messanger Cyclic Adenoside Monophosphate. Eur. Arc. Otorhinolarngology, 258 230-235 (2001).
23. Cho JH, Kurun YS, Jang HS, Kang JM, Won YS, Yoon HR. Long Term Use of Preservatives on Rat Nasal Respiratory Mucosa: Effects of Benzalkonium Chloride and Potassium Sorbate. Laryngoscope, 110 312-317 (2000).
24. Behl CR, Pimplaskar HK, Sileno AP Xia WJ, Gries WJ, Emeireles JC, et al. Optimization of Systemic Nasal Drug Delivery with Pharmaceutical Excipients. Adv. Drug Dev. Rev, 29 117-133 (1998).
25. Alpar HO, Bowen JC, Brown M R W. Effectiveness of Liposomes as Adjuvants of Orally and Nasally Administered Tetanus Toxoid. Int. J. Pharm. 88 335-344 (1992).
26. Alpar HO, Eyles JE, Williamson ED, Somava E. Intranasal Vaccination Against Plague, Tetanus Toxoid and Diphteria. Adv. Drug Del. Rev. 51 173-201 (2001).
27. Law SL, Huang KJ, Chou V H Y, Cherng JY. Enhancement of Nasal Absorption of Calcitonin Liposomes. J. Liposome Research, 11 165-174 (2001).
28. Hyde SC, Southern KW, Gileadi U, Fitzjohn KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Sorgi FL, Huang L, Cutbert AW, Evans MJ, Colledge WH, Higgins Gill DR. Rpeat Administration of DNA/liposomes to the Ephitelium of Patients with Cystic Fibrosis. Gene Therapy, 7 1156-1163 (2000).
29. Maitani Y, Asano S, Takahashi S, Nagagaki M, Nagai T. Permeability of Insulin Entrapped in Liposome Through the Nasal Mucosa of Rabbits. Chem. Pharm. Bull. 40 1569-1572 (1992).
30. Gonchorova EP, Ryzhikov AB, Bulychev LE, Lebedev LR, Poryvaev VD, Karpenko LI, Ilichev AA. A Study of Systems for Delivering Antigens for Intranasal Immunization Against Tick-Borne Encephalitis. Weiner Klinische Wochenschrift, 114 630-635 (2002).
31. Jung BH, Chung BC, Chung S, Lee M, Shin C. Prolonged Delivery of Nicotine in Rats via Nasal Administration of Proliposomes. J. Control. Rel. 66 73-79 (2000).
32. Bjork E, Erdman P. Degredable Starch Microspheres as a Nasal Delivery System for Insulin. Int. J. Pharm. 47 233-238 (1988).
33. Farraj NF, Johanson BR, Davis SS, Illum L. Nasal Administration of Insulin Using Bioadhesive Microspheres as a Delivery System. J. Control. Del, 13 253-261 (1990).
34. Ugwoke MI, Kaufmann G, Verbeke N, Kinget A. Intranasal Bioavailability of Apomorphine from Carboxymethyl Cellulose-based Drug Delivery Systems. Int. J. Pharm. 217 125-131 (2000).
35. Illum L, Jorgensen H, Bisgoard H, Krogsgoard Q, Rossing N. Bioadhesive Microspheres as a Potential Nasal Drug Delivery System. Int. J. Pharm. 39 189-199 (1987).
36. Ryden E, Erdman P. Effects of Polymers and Microspheres on the Nasal Absorption of Insulin in Rats. Int. J. Pharm., 83 1-10 (1992).
37. Leitner VM, Guggi D, Krauland AH, Bernkop-Schnurch A. Nasal Delivery of Human Growth Hormone, In Vitro and In Vivo of a Thiomer/Glutathione Microparticulate Delivery System. J. Control. Rel. 100 87-95 (2004).
38. Preda M, Leucuta SE. Oxprenolol-Loaded Bioadhesive Microspheres: Preparation and In Vivo Characterization. J. Microencap. 20 777-789 (2003).
39. Cerchiara T, Luppi B, Bigucci F, Zecchi V. Chitosan Salts as Nasal Sustained Delivery Systems for Peptide Drugs. J. Pharm. Pharmacol. 55 1623-1627 (2003).
40. Tengamnuay P, Sahamethapat A, Sailasuta A. Chitosan as Nasal Absorption Enhancers of Peptides: A Comparison Between Free Amine Chitosan and Soluble Salts. Int. J. Pharm, 217 53-67 (2000).
41. Vila A, Sanchez A, Janes K, Behrens I, Kiel J L V. Low Molecular Weight Chitosan Nanoparticles and Carriers for Nasal Vaccine Delivery in Mice. Eur. J. Pharm. Biopharm, 57 123-131 (2004).
42. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance Characteristics of Chitosan Based Formulatins in the Sheep Nasal Cavity. Int. J. Pharm. 218 183-191 (2001).
43. Fernandez-Urrusuno R, Romoni D, Calvo P, Alonso MJ. Development of a Freeze Dried Formulation of Insulin-loaded Chitosan Nanoparticles Intended for Nasal Adiministration. STP Pharma Sci. 9 4-10 (1999).
44. Fernandez-Urrusuno R, Calvo P, Remunon-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles. Pharm. Res, 16 1576-1581 (1999).
45. Morimoto K, Tabata H, Morisaka K. Nasal Absorption of Nifedipine from Gel Preparations in Rats. Chem. Pham. Bull. 35 3041-3044 (1987).
46. Morimoto K, Morisaka K, Kamada A. Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel. J. Pharm. Pharmacol. 37 134-136, (1985).
47. Ugwoke MI, Agu RU, Vanbilloen H, Baetens P, Verbeke N, Mortelmans L, Verbruggen A, Kinget R, Bormans G. Scintigraphic Evaluation in Rabbits of Nasal Drug Delivery Systems Based on Carbopol 971P and Carboxymethylcellulose. J. Control. Rel. 68 207-214 (2000).
48. Illum L, Farraj NF, Critchley H, Johansen BR, Davis SS. Enhanced Nasal Absorption of Insulin in Rats Using Lysophosphatidylcholine. Int. J. Pharm, 57 49-54 (1989).
49. Deponti R, Lardini E, Use of Chemical Enhancers for Nasal Drug Delivery. Drug Dev. Ind. Pharm. 17 1419-1436 (1991).
50. Hermens W A JJ, Hooymans PM, Verhoef JC, Merkus F W HM. Effects of Absorption Enhancers on Human Nasal Tissue Ciliary Movement in Vitro. Pharm. Res. 7 144-146 (1990).
51. Hedin L, Olsson B, Diczfalusy M, Flyg C, Petersson AS, Rosberg S, et al. Intranasal Administration of Human Growth Hormone (hGH) in Combination with a Membrane Permeation Enhancer in Patients with GH Deficiency: A Pharmacokinetic, Study. JCE & M, 76 962-967 (1993).
52. Kissel T, Drewe J, Bantle S, Rummelt A, Beglinger C. Tolerability and Absorbtion Enhancement of Intranasally Administered Octreotide by Sodium Taurodihydrofusidate in Healty Subjects. Pharm. Res. 9, 52-57 (1992).
53. Lee WA, Ennis RD, Longenecker JP, Bengtsson P. The Bioavailability of Intranasal Salmon Calcitonin in Healty Volunteers with and without a Permeation Enhancer. Pharm. Res. 11, 747-750 (1994).
54. Drejer K, Vaag A, Beck K, Hansen P, Sorensen Ar, Mygind N. Intranasal Administration of Insulin with Phospholipid as Absorption Enhancer. Pharmacokinetics in Nasal Subjects. Diabet. Med. 9, 335-340 (1992).
55. Mishima M, Okada S, Wakita Y, Nakano M. Promotion of Nasal Absorption of Insulin by Glycyrrhetinic Acid Derivatives. I. J. Pharmacobio-Dyn, 36, 12-31 (1989).
56. Behl CR, Pimplashar HK, Sileno AP, Xia WJ, Gries WJ, Emeireles JC, et al. Optimization of Systemic Nasal Drug Delivery with Pharmaceutical Excipients. Adv. Drug Del. Rev. 29, 117-133 (1998).
57. Marttin E, Verhoef JC, Merkus F W HM. Efficacy, Safety and Mechanism of Cyclodextrins as Absorption Enhancer in Nasal Delivery of Peptide and Protein Drugs. J. Drug Target, 6, 17-36 (1998).
58. Sinswat P, Temgamnuay P. Enhancing effect of Chitosan on Nasal Absorption of Calcitonin in Rats: Comparison with Hydroxypropyl-Alfa and Dimethyl Beta Cyclodextrins. Int. J. Pharm, 21, 220, 15-22 (2003).
59. Shao Z, Krishnamoorthy R, Mitra A. Cyclodextrins as Nasal Absorption Promoters of Insulin: Mechanistic Evaluations. Chem. Pharm. Bull. 40, 3100-3104 (1992).
60. Merkus F W HM, Verhoef JC, Romeijn SG, Schipper N G M. Absorption Enhancing Effect of Cyclodextrins on Intranasally Administrated Insulin in Rats. Pharm. Res. 8, 588-592 (1991).
61. Agerholm C, Bastholm L, Johanson PB, Nielsen MH, Elling F. Ephitelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoyl-L-cx-phosphatidylcholine and cx-cyclodextrins in Rabbits. J. Pharm. Sci. 83, 1706-1711 (1994).
62. Al-Ghananeem AM, Traboulsi AA, Dittert LW, Hussain AA. Targeted Brain Delivery of 17-Beta-Estradiol via Nasally Administered Water Soluble Prodrugs. AAPS Pharm Sci Tech. 3, E5 (2002).
63. Green GM. Alveolobronchiolar Transport Mechanisms. Arch. Int. Med. 131, 109 (1973).
64. Taylor K M G, Farr SJ. Liposomes for Pulmonary Drug Delivery. In: Liposomes in Drug Delivery, G Gregoriadis, AT Florence, M Patel (Eds), Harwood Academic Publishers, Switzerland, 95-109 (1993).
65. Yu I, Chien YW. Pulmonary Drug Delivery: Physiologic and Mechanistic Aspects, Critical Review. In: Therapeutic Drug Carrier Systems, 14, 395-453 (1997).
66. Taylor K M G, Farr SJ. Liposoemes for Pulmonary Drug Delivery. In: Liposomes in Drug Delivery. G Gregoriadis, AT Florence, M Patel (Eds), Harwood Academic Publishers, Switzerland, 111-133 (1993).
67. Gonda I, Schuster J. Pulmonary Delivery of Drugs by Inhalation. In: Modified Release Drug Delivery Technology. J Surarbrich (Ed), Marcel Dekker Inc., New York-Basel, pp: 807-815 (2003).
68. Fielding RM. The Use of Inhaled Liposome Formulations for Drug Delivery to the Lung and Systemic Circulation. Proc. West. Pharmacol. 32, 103-106 (1989).
69. Kitson C, Angel B, Judd D, Rothery S, Seville A, Huang L, Wadsworth SC, Cheng SH, Geddes DM, Alton E W FW. The Extra and Intracellular Barriers to Lipid Adenovirus Mediated Pulmonary Gene Transfer in Native Airway Epithelium. Gene Therapy, 6, 534-546 (1999).
70. Cockett MI. Technology Evaluation: Cystic Fibrosis Therapy. Current Opinion in the Molecular Therapeutics, 19, 279-283 (1998).